David Caudell to Histone Deacetylase Inhibitors
This is a "connection" page, showing publications David Caudell has written about Histone Deacetylase Inhibitors.
Connection Strength
0.306
-
Vieson MD, Gojmerac AM, Khan D, Dai R, van Duzer JH, Mazitschek R, Caudell DL, Liao X, Luo XM, Reilly CM. Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice. Histol Histopathol. 2017 Dec; 32(12):1317-1332.
Score: 0.150
-
Regna NL, Chafin CB, Hammond SE, Puthiyaveetil AG, Caudell DL, Reilly CM. Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo. Clin Immunol. 2014 Mar; 151(1):29-42.
Score: 0.121
-
Regna NL, Vieson MD, Gojmerac AM, Luo XM, Caudell DL, Reilly CM. HDAC expression and activity is upregulated in diseased lupus-prone mice. Int Immunopharmacol. 2015 Dec; 29(2):494-503.
Score: 0.034